By Nick Lavars For today’s sufferers of the blood cancer acute myeloid leukemia (AML), standard chemotherapy remains the most common course of treatment, but the risk of recurrence is high and occurs in almost half of patients. In search of therapies that can offer longer-term protection, scientists at Harvard University have developed a new type...